Clinical Trial Update: Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing ribociclib versus palbociclib in advanced/metastatic breast cancer within the HER2-enriched subtype; currently active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• KISQALI (ribociclib)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING